Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
President's trip paves way for more outcomesFamily of heiress who drowned are to sue her husband who was accused of killing herXinhua Commentary: Xi's Meeting with Ma Injects Positive Energy to Relations Across Taiwan StraitWater conservancy repairs were organized to ensure irrigation in YangzhouPresident's trip paves way for more outcomesFrance should bring rational voice to EU trade policy on ChinaA more inclusive path beneficial for multipolar worldDisturbing rise in teenage boys demanding rough sex and choking girls as young as 12Living in Downing Street was like being a prisoner in a soulless cageFrance should bring rational voice to EU trade policy on China
2.9569s , 6502.5 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Grasp news portal